Autologous cytokine-induced killer cell immunotherapy may improve overall survival in advanced malignant melanoma patients. (November 2017)

• Record Type: Journal Article
• Authors: Zhang, Yong; Zhu, Yu'nan; Zhao, Erjiang; He, Xiaolei; Zhao, Lingdi; Wang, Zibing; Fu, Xiaomin; Qi, Yalong; Ma, Baozhen; Song, Yongping; Gao, Quanli
• Is Part Of: Immunotherapy. Volume 9:Number 14(2017)
• Page Start: 1165
• Page End: 1174
• Publication Date: 2017-11
• Subjects: cytokine-induced killer cells -- immunotherapy -- malignant melanoma; Immunotherapy -- Periodicals; 615.37
• DOI: 10.2217/imt-2017-0061
• Languages: English
• ISSNs: 1750-743X

Abstract

Aims: Our study was conducted to explore the efficacy of autologous cytokine-induced killer (CIK) cells in patients with advanced malignant melanoma.Materials & Methods: Here we reviewed 113 stage IV malignant melanoma patients among which 68 patients received CIK cell immunotherapy alone, while 45 patients accepted CIK cell therapy combined with chemotherapy. Results: We found that the median survival time in CIK cell group was longer than the combined therapy group (21 vs 15 months, p = 0.07). In addition, serum hemoglobin level as well as monocyte proportion and lymphocyte count were associated with patients' survival time.Conclusions: These indicated that CIK cell immunotherapy might extend survival time in advanced malignant melanoma patients. Furthermore, serum hemoglobin level, monocyte proportion and lymphocyte count could be prognostic indicators for melanoma.